- Patients with advanced NSCLC who received microwave ablation (MWA) plus chemotherapy have better survival outcomes than those treated with chemotherapy alone, with tolerable adverse events (AEs).
Why this matters
- Although platinum-based doublet chemotherapy is the standard first-line treatment for patients with NSCLC without sensitizing mutations or high program death-ligand 1, studies suggest that chemotherapy alone has reached a therapeutic plateau.
- Multicenter, randomized, controlled, open-label, phase 3 trial.
- Patients with advanced NSCLC received MWA followed by chemotherapy (n=148) or chemotherapy alone (n=145).
- Funding: National Health and Family Planning Commission of the People’s Republic of China; others.
- Median PFS was significantly better in the MWA group:
- 10.3 vs 4.9 months (HR, 0.44; P<.0001>
- Median OS was significantly better in the MWA group:
- Not reached vs 12.4 months (HR, 0.38; P<.0001>
- Objective response rate was similar between groups.
- 89% of the MWA group achieved complete ablation, with local progression in 27 patients.
- Overall incidence of AEs was similar between groups.
- 76% of MWA group reported ablation-related complications, 20% of which were severe.
- No treatment-related deaths in either group.
- Gene mutation status was unknown for most patients.